{
  "docId": "019de071-1981-7442-94ed-ee285d10f59b",
  "docSlug": "c18efbd116f640ca1060cd96d0c18250",
  "documentTitle": "Alkermes | Results Presentation Deck | 31 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 31,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Slide provides status update on clinical trial enrollment as of May 25, 2021.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1981-7442-94ed-ee285d10f59b/11",
  "deckHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b",
  "deckJsonHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b.json",
  "deckAnchorHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.52,
        "y": 0.28
      },
      "kind": "callout",
      "text": "Key Study Features",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43158da3-2e96-4279-8d1e-f0c09b110455",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.07,
        "y": 0.37
      },
      "kind": "list",
      "text": "Advanced Melanoma Cohort (n=47) Advanced Renal Cell Carcinoma Cohort (n=27)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64aa73ae-df73-4628-8a46-3ae1239c8f6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.52,
        "y": 0.43
      },
      "kind": "list",
      "text": "Key inclusion criteria - progressed on: Immune checkpoint inhibitor (e.g., anti-PD-(L)1 with or without anti-CTLA-4) Targeted agent, as appropriate (e.g., BRAF inhibitor if BRAF-mut) Patients eligible to roll over to part C combination with pembrolizumab",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1b06abd-4c99-4240-b09b-1ac68ea50f73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.07,
        "y": 0.275
      },
      "kind": "paragraph",
      "text": "Part B: Monotherapy Dose Expansion Total Enrolled: 74 6 µg/kg IV nemvaleukin",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db281aab-d763-4782-9cee-a7d82976ac4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "ARTISTRY-1 Monotherapy Cohort: Enrollment Completed",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afac09ea-4f4f-4e7c-a64d-0afb8ef47482",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 9,
      "beatId": "d9955255-a32f-40ae-8cd0-621b7a3219ac",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The presentation provides detailed data on ARTISTRY-1 and ARTISTRY-2 clinical trials",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 9,
      "name": "Zoom In",
      "slug": "06-zoom-in",
      "bestFor": "Technical deep-dives, case studies, detailed analysis",
      "matchId": "d7735cef-12ea-4b86-b204-a8c9a7eb598c",
      "evidence": "The presentation provides detailed data on the clinical trials",
      "position": 0,
      "objective": "What are the safety and efficacy results of Nemvaleukin Alfa in ARTISTRY-1 and ARTISTRY-2 trials?",
      "structure": "The Big Picture -> Key Area of Focus -> Specific Detail -> Implication",
      "confidence": 0.8,
      "description": "Start broad, then progressively focus on specific details that prove your point"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}